bargain...it was...now gone...$2.50 costs....$3.50 revenue...9,000 tpa....EBITDA per share = 2.5 cents....
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%